Flow Cytometry Method Validation Protocols
Current Protocols · 2023-08 · 3 (8)
DOI: 10.1002/cpz1.868 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Protocols, online erschienen am 22.08.2023. Verfasst von Nithianandan Selliah und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cerba Research, Lake Success, New York. Hauptthemen laut MEDLINE: Research Design, Clinical Laboratory Services. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Analytical method validation provides a means to ensure that data are credible and reproducible. This article will provide a brief introduction to analytical method validation as applied to cellular analysis by flow cytometry, along with practical procedures for four different types of validation. The first, Basic Protocol 1 (the limited validation protocol), is recommended for research and non‐regulated laboratories. Next, Basic Protocol 2) presents a reasonable, fit‐for‐purpose validation approach appropriate for biopharma and research settings. Basic Protocol 3 addresses the type of validation performed in clinical laboratories for moderate‐risk tests developed in house. Finally, Basic Protocol 4 describes the process that should be applied whenever a method is being transferred from one facility to another. All four validation plans follow the fit‐for‐purpose validation approach, in which the validation parameters are selected based on the intended use of the assay. These validation protocols represent the minimal requirement and may not be applicable for every intended use such as high‐risk clinical assays or data to be used as a primary endpoint in a clinical trial. The recommendations presented here are consistent with the white papers published by the American Association of Pharmaceutical Scientists and the International Clinical Cytometry Society, as well as with Clinical Laboratory Standards Institute Guideline H62: Validation of Assays Performed by Flow Cytometry (CLSI, 2021). © 2023 Wiley Periodicals LLC. Basic Protocol 1 : Limited validation Basic Protocol 2 : Fit‐for‐purpose validation for biopharma and research settings Basic Protocol 3 : Validation for moderate clinical risk laboratory developed tests Basic Protocol 4 : Transfer validation This article was corrected on 25 January 2024. See the end of the full text for details.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cerba Research, Lake Success, New York.
- AstraZeneca, Gaithersburg, Maryland.
- Ozette Technologies, Seattle, Washington.
- Independent Consultant, San Clemente, California.
- Flow Contract Site Laboratory, LLC, Bothell, Washington.
- Novartis Institute for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
Zitieren
APA
Selliah, N., Nash, V., Eck, S., Green, C., Oldaker, T., Stewart, J., Vitaliti, A., & Litwin, V. (2023). Flow Cytometry Method Validation Protocols. Current Protocols, 3(8). https://doi.org/10.1002/cpz1.868
Vancouver
Selliah N, Nash V, Eck S, Green C, Oldaker T, Stewart J, et al. Flow Cytometry Method Validation Protocols. Current Protocols. 2023;3(8). doi:10.1002/cpz1.868
BibTeX
@article{Selliah2023,
author = {Selliah, Nithianandan and Nash, Veronica and Eck, Steven and Green, Cherie and Oldaker, Teri and Stewart, Jennifer and Vitaliti, Alessandra and Litwin, Virginia},
title = {Flow Cytometry Method Validation Protocols},
journal = {Current Protocols},
year = {2023},
volume = {3},
number = {8},
doi = {10.1002/cpz1.868}
}
EUVIMED